Ian Taylor Sells 9,020 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock

Arvinas, Inc. (NASDAQ:ARVN) insider Ian Taylor sold 9,020 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the transaction, the insider now directly owns 159,121 shares in the company, valued at $2,658,911.91. The trade was a 5.36 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Arvinas Price Performance

ARVN opened at $16.75 on Tuesday. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -6.05 and a beta of 1.88. The business’s 50-day moving average price is $18.44 and its two-hundred day moving average price is $22.85. Arvinas, Inc. has a 1 year low of $16.07 and a 1 year high of $51.51.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period last year, the firm posted ($2.53) EPS. Sell-side analysts anticipate that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ARVN. BTIG Research initiated coverage on shares of Arvinas in a research report on Tuesday, December 10th. They issued a “buy” rating and a $69.00 price target on the stock. Stephens assumed coverage on shares of Arvinas in a report on Monday, November 18th. They issued an “overweight” rating and a $55.00 target price on the stock. Stifel Nicolaus decreased their price target on shares of Arvinas from $63.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday, February 12th. Oppenheimer raised their price objective on Arvinas from $40.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Finally, Guggenheim reissued a “buy” rating and issued a $57.00 target price on shares of Arvinas in a research note on Wednesday, February 12th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat.com, Arvinas currently has an average rating of “Buy” and a consensus price target of $60.00.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new position in shares of Arvinas during the 4th quarter worth about $28,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Arvinas by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after acquiring an additional 440 shares during the last quarter. KBC Group NV raised its holdings in Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after acquiring an additional 1,255 shares in the last quarter. Quantbot Technologies LP boosted its position in Arvinas by 147.3% during the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after purchasing an additional 2,601 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in Arvinas in the fourth quarter valued at approximately $171,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.